Point-of-Care Troponin in 2017: Conference Lessons on Ruling Out MI

When the Society of Hospital Medicine gathered more than four thousand clinicians in Las Vegas for Hospital Medicine 2017, the schedule reflected a profession trying to compress diagnostic timelines. Squeezing rule-out pathways for suspected myocardial infarction into a single emergency department visit was no longer a research curiosity; it was an operational target. Among the workshops and posters, point-of-care troponin assays were treated as one of the more practical levers for meeting that target, especially for hospitals juggling winter surges, ambulance ramping, and the perennial pressure to admit or discharge faster.

For clinicians working along the Australian coastline, the conversations held in Nevada translated into immediate questions about local workflow. How do accelerated rule-out algorithms perform when bedside analysers sit beside a triage bay in Sydney's Royal Prince Alfred, or in the resuscitation area of a Perth tertiary centre? Which of the conference findings survive the trip across the Pacific, and which are reshaped by local regulatory and funding arrangements? The remainder of this article works through those questions, drawing on the Las Vegas programme while keeping Australian realities firmly in view.

A Shift in Bedside Cardiac Biomarkers

The 2017 meeting arrived during a quiet but consequential change in how troponin was being measured. Central laboratory platforms had spent several years migrating to high-sensitivity assays capable of detecting concentrations below the previous generation's analytical floor. Point-of-care devices were playing catch-up, but the conference speakers were careful to point out that bedside testing and high-sensitivity central assays were not direct substitutes. Each carried trade-offs in analytical precision, turnaround time, and clinical interpretation.

Presenters stressed that bedside troponin was not a replacement for the laboratory but a complement. In algorithms designed to discharge low-risk patients within an hour, the bedside result could anchor the first reading while the confirmatory sample travelled to the core lab. That dual-track approach was framed as a pragmatic answer to the reality that single-centre studies of 0/1-hour protocols had rarely used bedside assays, leaving Australian clinicians keen to see how the technology coped outside European study cohorts.

Conference Highlights on Accelerated Rule-Out Pathways

Several sessions devoted to chest pain accelerated pathways placed point-of-care testing near the centre of their protocols. Speakers reviewed cohorts where a single low bedside troponin, combined with a non-ischaemic electrocardiogram and a validated risk score, identified patients who could be safely observed and discharged without prolonged bed assignment. The audiences were reminded repeatedly that the rule-out performance rested on the assay's limit of detection, the timing of the draw, and the pre-test probability assigned at triage.

The recurring caution was that bedside assays differed across manufacturers, and not every cartridge had been validated against the Universal Definition of Myocardial Infarction used in Australian coronary care units. Speakers recommended that departments adopting point-of-care troponin build internal correlation studies against their central laboratory analyser before switching any chest pain pathway to rely on the bedside result. That message travelled well to Australian departments accustomed to validating new pathology platforms through their local pathology provider.

Inside a Crowded Australian Emergency Department

Walk through the front door of a busy tertiary emergency department in Melbourne, Brisbane, or Adelaide on a winter Sunday evening and the value of a short analytical turnaround becomes obvious. Ambulance queues stretch toward the street, four-hour National Emergency Access Targets loom, and triage nurses are weighing the trade-offs between fast rule-out and safe disposition. In that environment, a bedside troponin result that returns inside twenty minutes can shift a patient from an extended short-stay bed to discharge without occupying a monitored bay.

The conference case studies drew on health systems that resembled parts of the Australian network, with high-volume emergency short-stay units and shared decision-making between emergency physicians and inpatient teams. Common to most presentations was the suggestion that bedside testing changed the rhythm of the conversation with the patient, allowing risk to be discussed within the same clinical encounter rather than the next morning. Local champions of similar pathways in New South Wales and Queensland reported comparable benefits, although they noted the same staffing and quality-control caveats raised in Las Vegas.

Central Lab Compared With Bedside Analysers

The choice between a point-of-care platform and a central laboratory analyser is rarely a simple either-or decision. A side-by-side view of the two approaches, as discussed at Hospital Medicine 2017, helps clarify where each fits in an Australian chest pain service. The figures that follow summarise the trade-offs highlighted by conference speakers and echoed in subsequent Australian guideline commentary.

The take-home message from the conference was that these two columns describe complementary tools rather than rivals. Departments that treat them as substitutes tend to encounter either false reassurance from a less precise bedside assay or unnecessary delays when rapid rule-out is bottlenecked behind core laboratory transport.

Rural and Remote Realities Across the Continent

Few settings test the case for point-of-care troponin harder than remote Western Australia, the Top End of the Northern Territory, or the western reaches of Queensland. Royal Flying Doctor Service flights, narrow weather windows, and the absence of an on-site pathology laboratory mean that any blood test sent off-site can effectively rule out nothing on the same day. Conference presenters who worked in similar catchments across North America described bedside troponin as a genuine change in practice, allowing retrieval clinicians to initiate transfer decisions with biochemistry already in hand.

The Australian corollary surfaced in workshops focused on retrieval coordination. Speakers argued that, with appropriate quality control, a validated bedside troponin could allow a small rural hospital to keep a low-risk patient locally rather than committing a fixed-wing retrieval for what later proves to be a non-cardiac presentation. The practical obstacle is rarely the technology itself and more often the maintenance contract, the training time for rotating medical officers, and the governance linkage to a regional pathology service for lot-to-lot verification.

Reimbursement, Regulation, and the Local Paper Trail

Funding and governance questions drew more Australian audience questions than almost any other topic. The Therapeutic Goods Administration classifies troponin assays as Class 2 in vitro diagnostics, requiring Australian Register of Therapeutic Goods inclusion before bedside platforms can be marketed locally. Several presenters pointed out that not every device showcased in the Las Vegas exhibition hall had completed that pathway, and clinicians should confirm local approval before any procurement decision.

Reimbursement brings its own complexity. Standard troponin measurement is supported through items in the Medicare Benefits Schedule when requested by a medical practitioner and performed by an accredited pathology laboratory. Point-of-care testing performed wholly within a hospital emergency department may instead be funded through the activity-based arrangements agreed under the National Health Reform Agreement rather than a discrete schedule fee. Hospitals considering bedside troponin therefore need to work through their finance team as carefully as through their cardiology committee, and the Hospital Medicine 2017 clinical documentation refresher offers a useful starting point for capturing the rationale clearly in the patient record.

The conference programme also emphasised that any rule-out algorithm should be coupled with a documented escalation process for ambiguous results, ideally tied to the hospital's rapid response governance. An overview of rapid response patterns presented at Hospital Medicine 2017 showed how unclear escalation was a recurring root cause of deterioration following discharge, and troponin interpretation is no exception to that lesson.

For a department ready to act on the 2017 findings, the most concrete next step is to schedule a single multidisciplinary case review with emergency, cardiology, pathology, and nursing leads, and use it to map the local chest pain pathway against the conference algorithm before any change to bedside testing is approved.